3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
3
Phase 3
2
Phase 1/2
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Tumor-Agnostic
1
Genitourinary
1
Conditions
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Prostatic Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
8
Leukemia
8
Lymphoma, Non-Hodgkin
7
Burkitt Lymphoma
5
Hodgkin Disease
4
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Biphenotypic, Acute
3
Dendritic Cell Sarcoma, Interdigitating
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Urogenital Neoplasms
1
Thymoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Myasthenia Gravis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Prednisolone
×
Clear all
NCT00519285
2016-07-22
VENICE
Sanofi
Phase 3
Completed
1,224 enrolled
21 charts
NCT00822809
2012-10-03
CASIMAS
Neovii Biotech
Phase 3
Completed
230 enrolled